Literature DB >> 4555773

Field trial with human and equine influenza vaccines in children: protection and antibody titres.

A Wesselius-de Casparis, N Masurel, K F Kerrebijn.   

Abstract

A placebo-controlled influenza vaccination trial was carried out on 374 children in the winter of 1967-68. The children were randomly vaccinated with 300 CCA of A2/England/1/1966, 300 CCA of A/equine 2/Miami/1963, or with a placebo. During this winter an influenza outbreak occurred, caused by A2/Nederland/1968. The A2 vaccine yielded a protection rate of 58% (P = 0.02) and the A/equine 2 vaccine a rate of 19% (P = 0.33). Serological data revealed that all influenza infections occurred in subjects who had a pre-epidemic haemagglutination inhibition titre below 150. The antibody response against various human influenza A2 viruses and against the horse strain (A/equine 2) is discussed.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4555773      PMCID: PMC2480703     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  10 in total

1.  EXPERIMENTAL INFECTION OF HUMAN VOLUNTEERS WITH EQUINE INFLUENZA VIRUS.

Authors:  J A KASEL; R H ALFORD; V KNIGHT; G H WADDELL; M M SIGEL
Journal:  Nature       Date:  1965-04-03       Impact factor: 49.962

2.  The clinical epidemiology of Asian influenza.

Authors:  F M DAVENPORT; A V HENNESSY
Journal:  Ann Intern Med       Date:  1958-09       Impact factor: 25.391

3.  [Antibodies against type A Asian influenza virus in the normal population].

Authors:  R DAVOLI; O B CORSI
Journal:  Sperimentale       Date:  1957 Sep-Oct

4.  Pre-epidemic antibody against 1957 strain of Asiatic influenza in serum of older people living in the Netherlands.

Authors:  J MULDER; N MASUREL
Journal:  Lancet       Date:  1958-04-19       Impact factor: 79.321

5.  [Influenza-A virus as the cause of pandemics and epidemics].

Authors:  N Masurel
Journal:  Ned Tijdschr Geneeskd       Date:  1967-07-15

6.  Relation between Hong Kong virus and former human A2 isolates and the A-EQU12 virus in human sera collected before 1957.

Authors:  N Masurel
Journal:  Lancet       Date:  1969-05-03       Impact factor: 79.321

7.  Antibody response obtained by vaccination with the influenza A-Equi 2 virus in man.

Authors:  N Masurel
Journal:  Nature       Date:  1968-04-06       Impact factor: 49.962

8.  [A new manifestation of the influenza A virus].

Authors:  N Masurel
Journal:  Ned Tijdschr Geneeskd       Date:  1968-10-19

9.  Studies on the content of antibodies for equine influenza viruses in human sera.

Authors:  N Masurel; J Mulder
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

10.  Serological characteristics of a "new" serotype of influenza A virus: the Hong Kong strain.

Authors:  N Masurel
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

  10 in total
  10 in total

1.  Influenza update: a review of currently available vaccines.

Authors:  Lisa R Clayville
Journal:  P T       Date:  2011-10

2.  A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes.

Authors:  Laurent Coudeville; Philippe Andre; Fabrice Bailleux; Françoise Weber; Stanley Plotkin
Journal:  Hum Vaccin       Date:  2010-10-01

Review 3.  Vaccines for preventing influenza in healthy children.

Authors:  Tom Jefferson; Alessandro Rivetti; Carlo Di Pietrantonj; Vittorio Demicheli; Eliana Ferroni
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

Review 4.  Prevention of influenza in the general population.

Authors:  Joanne M Langley; Marie E Faughnan
Journal:  CMAJ       Date:  2004-11-09       Impact factor: 8.262

5.  Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses.

Authors:  J R Davies; E A Grilli
Journal:  Epidemiol Infect       Date:  1989-04       Impact factor: 2.451

6.  Haemagglutination-inhibition antibodies against influenza A and influenza B in maternal and neonatal sera.

Authors:  N Masurel; J I de Bruijne; H A Beuningh; H J Schouten
Journal:  J Hyg (Lond)       Date:  1978-02

7.  A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection.

Authors:  N Masurel; J Laufer
Journal:  J Hyg (Lond)       Date:  1984-06

8.  Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus.

Authors:  N Masurel; P Ophof; P de Jong
Journal:  J Hyg (Lond)       Date:  1981-10

Review 9.  Vaccines for preventing influenza in healthy children.

Authors:  Tom Jefferson; Alessandro Rivetti; Carlo Di Pietrantonj; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01

10.  Immunogenicity of a reduced dose of A/H3N2 in the 2005 southern hemisphere formulation of inactivated split influenza vaccine.

Authors:  Christopher Burrell; Robert Booy; Nicholas Wood; Anne-Marie Egan; David Taverner; Ken Williams; Winston Liauw; Alan Moskwa; Stephanie Pepin-Covatta; Melanie Saville
Journal:  Influenza Other Respir Viruses       Date:  2008-05       Impact factor: 4.380

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.